Fusion Pharmaceuticals Stock Price, News & Analysis (NASDAQ:FUSN) $5.74 +0.34 (+6.30%) (As of 12/7/2023 ET) Add Compare Share Share Today's Range$5.27▼$5.8550-Day Range$2.48▼$5.7452-Week Range$2.30▼$5.85Volume409,629 shsAverage Volume182,544 shsMarket Capitalization$415.61 millionP/E RatioN/ADividend YieldN/APrice Target$12.20 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Fusion Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside112.5% Upside$12.20 Price TargetShort InterestHealthy0.13% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.92Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.47) to ($1.40) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.47 out of 5 starsMedical Sector152nd out of 960 stocksBiological Products, Except Diagnostic Industry16th out of 141 stocks 3.5 Analyst's Opinion Consensus RatingFusion Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.20, Fusion Pharmaceuticals has a forecasted upside of 112.5% from its current price of $5.74.Amount of Analyst CoverageFusion Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.13% of the outstanding shares of Fusion Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverFusion Pharmaceuticals has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Fusion Pharmaceuticals has recently decreased by 35.93%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldFusion Pharmaceuticals does not currently pay a dividend.Dividend GrowthFusion Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for FUSN. Previous Next 3.8 News and Social Media Coverage News SentimentFusion Pharmaceuticals has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Fusion Pharmaceuticals this week, compared to 1 article on an average week.Search Interest3 people have searched for FUSN on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows2 people have added Fusion Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fusion Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.75% of the stock of Fusion Pharmaceuticals is held by insiders.Percentage Held by Institutions72.85% of the stock of Fusion Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Fusion Pharmaceuticals are expected to grow in the coming year, from ($1.47) to ($1.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fusion Pharmaceuticals is -3.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fusion Pharmaceuticals is -3.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFusion Pharmaceuticals has a P/B Ratio of 1.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Fusion Pharmaceuticals Stock (NASDAQ:FUSN)Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. Its lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers. The company has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.Read More FUSN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FUSN Stock News HeadlinesDecember 1, 2023 | americanbankingnews.comFusion Pharmaceuticals Inc. to Post FY2023 Earnings of ($1.40) Per Share, B. Riley Forecasts (NASDAQ:FUSN)November 27, 2023 | finance.yahoo.comHow Much Upside is Left in Fusion Pharmaceuticals Inc. (FUSN)? Wall Street Analysts Think 162%December 8, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 16, 2023 | markets.businessinsider.comBWXT Medical To Assist Fusion In Actinium-225 Production By Providing Access To Generator TechnologyNovember 16, 2023 | financialpost.comBWXT Medical Expands Collaboration with Fusion Pharmaceuticals Through Strengthened Actinium Supply and Access to Generator TechnologyNovember 9, 2023 | markets.businessinsider.comPositive Outlook on Fusion Pharmaceuticals: Analysis of Strong Cash Position, Potential First-in-Class Status, and Advancing Clinical AssetsNovember 8, 2023 | morningstar.comFusion Pharmaceuticals Inc Ordinary Shares FUSNNovember 8, 2023 | markets.businessinsider.comFusion Pharmaceuticals: Promising Clinical Progress and Solid Financial Health Bolster Buy RatingDecember 8, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 7, 2023 | finance.yahoo.comFusion Pharmaceuticals Inc. (FUSN) Reports Q3 Loss, Tops Revenue EstimatesNovember 7, 2023 | finance.yahoo.comFusion Pharmaceuticals Inc (FUSN) Reports Q3 2023 Financial Results and Clinical Program UpdatesNovember 7, 2023 | finance.yahoo.comFusion Pharmaceuticals Announces Third Quarter 2023 Financial Results and Clinical Program UpdatesOctober 26, 2023 | markets.businessinsider.comFusion Pharmaceuticals: Potential Growth Catalysts and Market Opportunities Justify Buy RatingOctober 17, 2023 | finance.yahoo.comFusion Pharmaceuticals Inc.'s (NASDAQ:FUSN) high institutional ownership speaks for itself as stock continues to impress, up 13% over last weekOctober 16, 2023 | finance.yahoo.comFusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its Board of DirectorsOctober 12, 2023 | markets.businessinsider.comFusion Pharma Presents Preclinical Data Demonstrating Potent Anti-tumor Activity Of FPI-2068October 12, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Incyte (INCY) and Fusion Pharmaceuticals (FUSN)October 4, 2023 | msn.comB. Riley Securities Reiterates Fusion Pharmaceuticals (FUSN) Buy RecommendationSeptember 30, 2023 | msn.comOppenheimer Initiates Coverage of Fusion Pharmaceuticals (FUSN) with Outperform RecommendationSeptember 5, 2023 | finance.yahoo.comFusion Pharmaceuticals to Present at Upcoming September Investor ConferencesAugust 29, 2023 | msn.comRaymond James Maintains Fusion Pharmaceuticals (FUSN) Outperform RecommendationAugust 14, 2023 | finance.yahoo.com10 Oversold Penny Stocks To BuyAugust 13, 2023 | markets.businessinsider.comFusion Pharmaceuticals (FUSN) Gets a Buy from Truist FinancialAugust 8, 2023 | finance.yahoo.comFusion Pharmaceuticals Inc. (FUSN) Reports Q2 Loss, Misses Revenue EstimatesAugust 8, 2023 | finance.yahoo.comFusion Pharmaceuticals Announces Second Quarter 2023 Financial Results and Clinical Program UpdatesJune 29, 2023 | msn.comWedbush Reiterates Fusion Pharmaceuticals (FUSN) Outperform RecommendationJune 29, 2023 | finance.yahoo.comOne Fusion Pharmaceuticals Insider Raised Stake By 370% In Previous YearSee More Headlines Receive FUSN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fusion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2023Today12/07/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/21/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FUSN CUSIPN/A CIK1805890 Webfusionpharma.com Phone289-799-0891FaxN/AEmployees101Year FoundedN/APrice Target and Rating Average Stock Price Target$12.20 High Stock Price Target$13.00 Low Stock Price Target$10.00 Potential Upside/Downside+112.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-87,610,000.00 Net Margins-4,136.55% Pretax Margin-4,175.00% Return on Equity-48.42% Return on Assets-36.27% Debt Debt-to-Equity Ratio0.18 Current Ratio11.63 Quick Ratio11.63 Sales & Book Value Annual Sales$2.21 million Price / Sales188.23 Cash FlowN/A Price / Cash FlowN/A Book Value$3.62 per share Price / Book1.59Miscellaneous Outstanding Shares72,406,000Free Float66,795,000Market Cap$415.61 million OptionableNot Optionable Beta-1.10 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. John F. Valliant Ph.D. (Age 53)Founder, CEO & Director Comp: $864.72kMr. John J. Crowley CPA (Age 49)Chief Financial Officer Comp: $670.1kDr. Eric Burak Ph.D. (Age 58)Chief Technology Officer Comp: $638.04kMr. Mohit Rawat (Age 43)President & Chief Business Officer Dr. Christopher Paul Leamon Ph.D. (Age 57)Chief Scientific Officer Ms. Amanda CraySenior Director of Investor Relations & Corporate CommunicationsMs. Maria D. Stahl (Age 52)Chief Legal Officer Mr. Eric S. Hoffman Ph.D. (Age 53)Senior Vice President of Business Development Dr. Cara Ferreira Ph.D.Chief of StaffDr. Joanne SchindlerExecutive Vice President of Medical Director & Clinical DevelopmentMore ExecutivesKey CompetitorsProKidneyNASDAQ:PROKReplimune GroupNASDAQ:REPLLexeo TherapeuticsNASDAQ:LXEOOrchard TherapeuticsNASDAQ:ORTXCullinan OncologyNASDAQ:CGEMView All CompetitorsInstitutional OwnershipAvidity Partners Management LPBought 81,850 shares on 11/14/2023Ownership: 7.985%Federated Hermes Inc.Bought 50,000 shares on 11/13/2023Ownership: 14.755%FMR LLCSold 503,609 shares on 11/13/2023Ownership: 5.770%Forefront Analytics LLCBought 13,610 shares on 11/8/2023Ownership: 0.049%Eagle Health Investments LPSold 100,601 shares on 10/27/2023Ownership: 0.840%View All Institutional Transactions FUSN Stock Analysis - Frequently Asked Questions Should I buy or sell Fusion Pharmaceuticals stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fusion Pharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" FUSN shares. View FUSN analyst ratings or view top-rated stocks. What is Fusion Pharmaceuticals' stock price target for 2024? 6 analysts have issued twelve-month target prices for Fusion Pharmaceuticals' stock. Their FUSN share price targets range from $10.00 to $13.00. On average, they expect the company's share price to reach $12.20 in the next twelve months. This suggests a possible upside of 112.5% from the stock's current price. View analysts price targets for FUSN or view top-rated stocks among Wall Street analysts. How have FUSN shares performed in 2023? Fusion Pharmaceuticals' stock was trading at $3.15 at the beginning of 2023. Since then, FUSN stock has increased by 82.2% and is now trading at $5.74. View the best growth stocks for 2023 here. Are investors shorting Fusion Pharmaceuticals? Fusion Pharmaceuticals saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 92,200 shares, a decline of 35.9% from the October 31st total of 143,900 shares. Based on an average daily volume of 180,200 shares, the days-to-cover ratio is currently 0.5 days. View Fusion Pharmaceuticals' Short Interest. When is Fusion Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024. View our FUSN earnings forecast. How were Fusion Pharmaceuticals' earnings last quarter? Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) announced its earnings results on Tuesday, November, 7th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.15. The company had revenue of $2.01 million for the quarter, compared to analyst estimates of $0.41 million. Fusion Pharmaceuticals had a negative trailing twelve-month return on equity of 48.42% and a negative net margin of 4,136.55%. What other stocks do shareholders of Fusion Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fusion Pharmaceuticals investors own include Overstock.com (OSTK), U.S. Xpress Enterprises (USX), Camping World (CWH), DocuSign (DOCU), Pfizer (PFE), Pure Storage (PSTG), CrowdStrike (CRWD), Livongo Health (LVGO), NVIDIA (NVDA) and OPKO Health (OPK). When did Fusion Pharmaceuticals IPO? (FUSN) raised $126 million in an initial public offering (IPO) on Friday, June 26th 2020. The company issued 8,400,000 shares at $14.00-$16.00 per share. Morgan Stanley, Jefferies and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Fusion Pharmaceuticals' major shareholders? Fusion Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Federated Hermes Inc. (14.75%), Avidity Partners Management LP (7.98%), FMR LLC (5.77%), Eagle Health Investments LP (0.84%), Forefront Analytics LLC (0.05%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Adams Street Partners Llc, John Valliant and Steven Gannon. View institutional ownership trends. How do I buy shares of Fusion Pharmaceuticals? Shares of FUSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:FUSN) was last updated on 12/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fusion Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.